CD276 and neoplasm: A preclinical study conducted by Scribner et al. showed that the single administration of MGC018, an antibody of B7-H3, achieved a 98% reduction in head and neck xenografts, indicating that the targeting of B7-H3 in CAR-T cell therapy exerts an anti-tumor effect in HNSCC treatment [47].